Catabasis Pharmaceuticals Stock Price

-0.10 (-3.64%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Catabasis Pharmaceuticals Inc CATB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.10 -3.64% 2.65 19:29:26
Open Price Low Price High Price Close Price Prev Close
2.78 2.6201 2.82 2.65 2.75
Bid Price Ask Price Spread News
2.65 2.75 0.10 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,293 845,353 $ 2.70 $ 2,281,265 1,438,333 1.25 - 8.59
Last Trade Time Type Quantity Stock Price Currency
19:56:24 formt 100 $ 2.65 USD

Catabasis Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 53.22M 20.08M 17.01M $ - $ - -2.35 -1.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Catabasis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CATB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.632.842.522.71733,3790.020.76%
1 Month2.132.842.012.45932,4160.5224.41%
3 Months1.363.251.272.035,369,0821.2994.85%
6 Months6.678.591.252.252,786,191-4.02-60.27%
1 Year5.938.591.252.491,473,110-3.28-55.31%
3 Years15.0023.801.255.33797,694-12.35-82.33%
5 Years67.0081.501.2511.17697,116-64.35-96.04%

Catabasis Pharmaceuticals Description

Catabasis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted, a linker-drug discovery platform. The company's primary focus is on treatments for rare diseases. Its product pipeline includes CAT-1004, an oral small molecule for the treatment of Duchenne muscular dystrophy, CAT-2054 for the treatment of hypercholesterolemia and CAT-4001 which is used for the treatment of rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Your Recent History
Catabasis ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.